8 results on '"Mengjie Ding"'
Search Results
2. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China
- Author
-
Qing, Wen, Jingjing, Ge, Yaxin, Lei, Yue, Zhang, Xiaoshuang, Kong, Wenhua, Wang, Huting, Hou, Zeyuan, Wang, Siyu, Qian, Mengjie, Ding, Meng, Dong, Linan, Zhu, Mingzhi, Zhang, Xudong, Zhang, and Qingjiang, Chen
- Subjects
Cancer Research ,Oncology ,General Medicine - Abstract
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) has been regarded as the standard treatment regimen for classical Hodgkin lymphoma. In recent years, ABVD-like regimens, which emerged due to shortages and the lung toxicity of bleomycin or the emergence of immune checkpoint inhibitors and antibody-drug conjugates, may be favorable, but have not yet been tested.We compared the outcomes of ABVD with ABVD-like regimens, which include bleomycin was completely or partially omitted; meanwhile, etoposide or PD-1 inhibitors were added.5-Year progression-free survival (PFS) was higher for ABVD than ABVD-like regimens in young patients (82.1% vs. 67.0%, p = 0.029), patients with serum beta-2 microglobulin (β2-MG) ≥ 1.85 mg/L (75.8% vs. 57.6%, p = 0.046), and advanced-stage patients with IPS score 4-7(63.1%, 18.3%, p = 0.038). For elderly (60.5% vs.76.1%, p = 0.089), patients with β2-MG 1.85 mg/L (83.1% vs 76.1%, p = 0.282), and advanced-stage patients with IPS score 0-3(84.6% vs. 81.3%, p = 0.476), 5-year PFS for ABVD did not differ from ABVD-like regimens. Elderly patients treated with bleomycin-free regimens showed a better survival trend compared with ABVD (99.3% vs. 61.3%, p = 0.270).ABVD is superior to ABVD-like regimens in achieving PFS in young patients or patients with poor prognosis including high IPS score and β2-MG level. ABVD-like regimens are as effective as ABVD in elderly or low-risk patients including low IPS score and β2-MG level; elderly patients treated with bleomycin-free regimens exhibit a better survival trend compared with ABVD.
- Published
- 2022
- Full Text
- View/download PDF
3. Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial
- Author
-
Xinhua Wang, Lei Zhang, Xiangli Liu, Xin Li, Ling Li, Xiaorui Fu, Zhenchang Sun, Jingjing Wu, Xudong Zhang, Jiaqin Yan, Yu Chang, Feifei Nan, Zhiyuan Zhou, Xiaolong Wu, Li Tian, Minrui Ma, Zhaoming Li, Hui Yu, Linan Zhu, Yingjun Wang, Cunzhen Shi, Xiaoyan Feng, Jiwei Li, Mengjie Ding, Jieming Zhang, Meng Dong, Hongwei Xue, Jinghua Wang, Liqun Zou, Liping Su, Jianqiu Wu, Lihong Liu, Huizheng Bao, Liling Zhang, Yanzhen Guo, Shuxia Guo, Yi Lu, Ken H. Young, Wencai Li, and Mingzhi Zhang
- Subjects
Adult ,Killer Cells, Natural ,Lymphoma, Extranodal NK-T-Cell ,Male ,Cancer Research ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Asparaginase ,Humans ,Female ,Middle Aged ,Dexamethasone ,Original Investigation - Abstract
IMPORTANCE: The L-asparaginase–based SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy regimen has shown higher response rates and survival benefit over an anthracycline-containing regimen. However, the safety profile was not satisfied. A well-tolerated regimen with promising efficacy is lacking. OBJECTIVE: To compare the efficacy and safety of the DDGP (dexamethasone, cisplatin, gemcitabine, and pegaspargase) regimen with the SMILE regimen in newly diagnosed advanced-stage (III/IV) extranodal natural killer/T-cell lymphoma (ENKL). DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, multicenter, randomized clinical trial that took place across 12 participating hospitals in China from January 2011 to February 2019. Patients were eligible if they were 14 to 70 years old with newly diagnosed ENKL in stages III/IV and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Eligible patients were evenly randomized to either the DDGP or SMILE group. INTERVENTIONS: Patients in each group were treated with the assigned regimen every 21 days for 6 cycles. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS), and secondary end points included overall response rate and overall survival (OS). The adverse events between the DDGP and SMILE groups were compared. RESULTS: Among the 87 randomized patients, 80 received treatment (40 in the DDGP group and 40 in the SMILE group); the median (IQR) age was 43 (12) years, and 51 (64%) were male. The baseline characteristics were similar between the groups. At a median follow-up of 41.5 months, the median PFS was not reached in the DDGP group vs 6.8 months in the SMILE group (HR, 0.42; 95% CI, 0.23-0.77; P = .004), and the median OS was not reached in the DDGP group vs 75.2 months in the SMILE group (HR, 0.41; 95% CI, 0.19-0.89, P = .02). The PFS rate at 3 years and OS rate at 5 years were higher in the DDGP group vs the SMILE group (3-year PFS, 56.6% vs 41.8%; 5-year OS, 74.3% vs 51.7%). The overall response rate was higher in the DDGP group than in the SMILE group (90.0% vs 60.0%; P = .002). Grade 3 and 4 hematologic toxic effects were more frequently reported in the SMILE group vs the DDGP group (leukopenia, 85.0% vs 62.5%; neutropenia, 85.0% vs 65.0%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the DDGP regimen showed promising preliminary results for patients with newly diagnosed local advanced ENKL. A confirmation trial based on larger population is warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01501149
- Published
- 2022
4. Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
- Author
-
Meng Dong, Yu Chang, Xudong Zhang, Xiaorui Fu, Jingjing Wu, Zhenchang Sun, Xin Li, Mingzhi Zhang, Lei Zhang, Feifei Nan, Xiaolong Wu, Jiaqian Yan, Songtao Niu, Zhiyuan Zhou, Linan Zhu, Fenghua Gao, Jieming Zhang, Xinhua Wang, Ling Li, Hui Yu, Wenhua Wang, Mengjie Ding, and Zhaoming Li
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Primary central nervous system lymphoma ,Induction chemotherapy ,medicine.disease ,Regimen ,Pemetrexed ,Tolerability ,Internal medicine ,Medicine ,Fotemustine ,Rituximab ,business ,medicine.drug - Abstract
Objective: This study aimed to evaluate the safety, efficacy, and feasibility of the rituximab, fotemustine, pemetrexed, and dexamethasone (R-FPD) regimen followed by whole-brain radiotherapy (WBRT) for patients with primary central nervous system lymphoma (PCNSL). Methods: A prospective, single-center phase II clinical trial was conducted. Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied. The R-FPD regimen consisted of rituximab (375 mg/m2 i.v. on D0), fotemustine (100 mg/m2 i.v. on D1), pemetrexed (600 mg/m2 i.v. on D1), and dexamethasone (40 mg i.v. on D1-5). Patients 60 years or younger who showed a complete response (CR) were treated with 23.4 Gy of WBRT after the end of chemotherapy; those older than 60 years with CR were treated with a wait-and-see approach; and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy + local tumor field irradiation up to 45 Gy, regardless of age. Results: A total of 30 patients were included. After 2 cycles, the objective response rate (ORR) was 96.5% (28/29, 1 CR, 27 PR, 0 SD, and 1 PD). After 4 cycles, the ORR was 73.1% (19/26, 11 CR, 8 PR, 4 SD, and 3 PD). After WBRT, the ORR was 90.9% (10/11, 7 CR, 3 PR, and 1 SD). The grade III and IV toxicity responses were mainly leukopenia (20.0%), thrombocytopenia (23.3%), and anemia (10.0%). Conclusions: Fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes, providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.
- Published
- 2021
5. Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
- Author
-
Xudong Zhang, Xin Wang, Qing Leng, Xiaohui Lu, Mengjie Ding, Shuangshuang Guo, Fei Chen, Xiaorui Fu, Meng Dong, Junxia Hu, Ling Li, Jingjing Wu, Meifeng Yin, Xinhua Wang, Zhenchang Sun, Lei Zhang, Xin Li, Qingjiang Chen, Dianbao Zhang, Wanqiu Yang, Linan Zhu, and Mingzhi Zhang
- Subjects
0301 basic medicine ,safety ,medicine.medical_specialty ,Cancer Research ,medicine.medical_treatment ,Decitabine ,Neutropenia ,DHAP Regimen ,chemotherapy ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,DHAP ,medicine ,modified DHAP regimen ,RC254-282 ,Chemotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Clinical Trial ,diffuse large B cell lymphoma ,Regimen ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cytarabine ,business ,Diffuse large B-cell lymphoma ,decitabine ,medicine.drug - Abstract
ObjectiveThe prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in R/R-DLBCL patients who failed second-line treatment.MethodsTwenty-one R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP regimen. The primary endpoints were overall response rate (ORR) and safety. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).ResultsORR reached 50% (complete response rate, 35%), five patients (25%) had stable disease (SD) with disease control rate (DCR) of 75%. Subgroup analysis revealed patients over fifty years old had a higher complete response rate compared to younger patients (P = 0.005), and relapsed patients had a better complete response rate than refractory patients (P = 0.031). Median PFS was 7 months (95% confidence interval, 5.1-8.9 months). Median OS was not achieved. One-year OS was 59.0% (95% CI, 35.5%-82.5%), and two-year OS was 51.6% (95% confidence interval, 26.9%-76.3%). The main adverse events (AEs) were grade 3/4 hematologic toxicities such as neutropenia (90%), anemia (50%), and thrombocytopenia (70%). Other main non-hematologic AEs were grade 1/2 nausea/vomiting (40%) and infection (50%). No renal toxicity or treatment-related death occurred.ConclusionDecitabine with a modified DHAP regimen can improve the treatment response and prognosis of R/R-DLBCL patients with good tolerance to AEs, suggesting this regimen has potential as a possible new treatment option for R/R-DLBCL patients after second-line treatment failure.Clinical Trial RegistrationClinicalTrials.gov, identifier: NCT03579082.
- Published
- 2021
- Full Text
- View/download PDF
6. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway
- Author
-
Qingjiang Chen, Mengjie Ding, Yue Zhang, Ze-Yuan Wang, Xianting Ran, Mingzhi Zhang, Meng Dong, Siyu Qian, Xudong Zhang, Huting Hou, and Shaoxuan Wu
- Subjects
Biophysics ,Mice, Nude ,Apoptosis ,Protein Serine-Threonine Kinases ,Biochemistry ,Models, Biological ,Mice ,hemic and lymphatic diseases ,Cell Line, Tumor ,Animals ,Humans ,Hippo Signaling Pathway ,Molecular Biology ,Wnt Signaling Pathway ,beta Catenin ,Adaptor Proteins, Signal Transducing ,Cell Proliferation ,YAP1 ,Hippo signaling pathway ,Gene knockdown ,GPNMB ,Membrane Glycoproteins ,Chemistry ,Cell growth ,Wnt signaling pathway ,YAP-Signaling Proteins ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Gene Knockdown Techniques ,Cancer research ,Disease Progression ,Heterografts ,Female ,Lymphoma, Large B-Cell, Diffuse ,Signal transduction ,Transcription Factors - Abstract
Glycoprotein non-metastatic melanoma protein B (GPNMB) has been confirmed to be related to the pathogenesis of tumors. However, the potential impact of GPNMB on the progression of diffuse large B-cell lymphoma (DLBCL) is unclear. In this study, the expression levels of GPNMB and Yes-associated protein (YAP) were analyzed using qRT-PCT and Western blot assay. Cell counting kit-8, EdU, and flow cytometry assays were used to detect the proliferation and apoptosis of DLBCL cells. A nude mice xenograft model was established for in vivo research. Results showed that GPNMB and YAP1 were upregulated in DLBCL cell lines. Knockdown of GPNMB inhibited cell proliferation and promoted apoptosis in DLBCL cells. Additionally, the expression levels of YAP1 and the downstream effector of Hippo pathway (c-myc) were markedly decreased when GPNMB was knocked down. Moreover, knockdown of GPNMB inhibited the nuclear translocation of β-catenin protein, which could be abolished by YAP1 overexpression. Simultaneously, the anti-proliferative and pro-apoptotic effects of GPNMB knockdown could be reversed by YAP1 overexpression or LiCl (the activator of Wnt/β-catenin pathway). Furthermore, the mice xenograft model confirmed that inhibition of GPNMB restrained the tumorigenesis of DLBCL in vivo. In conclusion, GPNMB could partly activate the Wnt/β-catenin signaling pathway by targeting YAP1, so as to participate in tumorigenesis of DLBCL.
- Published
- 2021
7. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma
- Author
-
Wanqiu Yang, Zhenzhen Yang, Xinhua Wang, Xiangke Li, Feng Wang, Zhenchang Sun, Mingzhi Zhang, Mengjie Ding, Zhaoming Li, Jingjing Wu, Lei Zhang, Linan Zhu, Meifeng Yin, Xiaorui Fu, Songtao Niu, and Xudong Zhang
- Subjects
0301 basic medicine ,Antineoplastic Agents ,Biology ,Biochemistry ,Cell Line ,Proto-Oncogene Proteins c-myc ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,medicine ,Humans ,Small nucleolar RNA ,Molecular Biology ,Gene ,Cell Proliferation ,Cisplatin ,Cell Biology ,Natural killer T cell ,medicine.disease ,Long non-coding RNA ,Lymphoma ,Gene Expression Regulation, Neoplastic ,Lymphoma, Extranodal NK-T-Cell ,030104 developmental biology ,Cell culture ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,RNA, Long Noncoding ,medicine.drug - Abstract
Nasal-type natural killer/T-cell lymphoma (NKTCL) is an aggressive malignancy with poor outcomes. The treatment of NKTCL requires intensive chemotherapy. Long noncoding RNAs (lncRNAs) have been implicated in many cancers, including NKTCL. The elucidation of the multidrug resistance (MDR) may greatly contribute to explore novel therapeutic strategies. Herein, we explored the roles and potential regulatory mechanism of lncRNAs small nucleolar RNA host gene 12 (SNHG12) in MDR of NKTCL. We found that SNHG12 was upregulated in NKTCL tissue sections, and its high expression was positively correlated with clinical grade of malignancy of NKTCL. c-Myc and SNHG12 expression was upregulated in NKTCL cell lines. c-Myc- and SNHG12 overexpression promoted proliferation and inhibited sensitivity to cisplatin (CDDP) in NK/T-cell lymphoma cell line YTS cells, and c-Myc and SNHG12-downregulation inhibited proliferation and enhanced sensitivity to CDDP in SNK-6 cells. Moreover, c-Myc- and SNHG12 overexpression increased Ki67 and P-gp expression in YTS cells, whereas c-Myc and SNHG12-downregulation reduced the Ki67 and P-gp expression in SNK-6 cells. Correlational analyses revealed that c-Myc expression was positively correlated with SNHG12 expression in NKTCL tissues. Mechanism research showed that SNHG12 was a direct transcriptional target of c-Myc and c-Myc promoted SNHG12 expression in NKTCL cell lines. Further research showed that SNHG12 overexpression reversed the effects of c-Myc downregulation on proliferation and sensitivity to CDDP in NKTCL cell lines. Taken together, our findings first report that c-Myc mediated upregulation of SNHG12 promotes proliferation and inhibits drug sensitivity in NKTCL, which provides new insights into the therapeutic target for NKTCL.
- Published
- 2018
8. TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
- Author
-
Mengjie Ding, Zhaoming Li, Xiangke Li, Feng Wang, Meifeng Yin, Jingjing Wu, Zhenchang Sun, Xinhua Wang, Wanqiu Yang, Songtao Niu, Zhenzhen Yang, Xudong Zhang, Linan Zhu, Lei Zhang, Xiaorui Fu, and Mingzhi Zhang
- Subjects
0301 basic medicine ,Male ,Esophageal Neoplasms ,Carcinogenesis ,Proliferation ,lcsh:Medicine ,Down-Regulation ,Mice, Nude ,Apoptosis ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Gentamicin protection assay ,Cell Line, Tumor ,Carcinoma ,medicine ,Wnt/β-catenin pathway ,Animals ,Humans ,Neoplasm Invasiveness ,Wnt Signaling Pathway ,Aged ,Cell Proliferation ,Mice, Inbred BALB C ,Chemistry ,Cell growth ,Research ,lcsh:R ,Wnt signaling pathway ,Intracellular Signaling Peptides and Proteins ,General Medicine ,Middle Aged ,medicine.disease ,Xenograft Model Antitumor Assays ,TIPE2 ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Esophageal carcinoma ,030220 oncology & carcinogenesis ,Catenin ,Tumorigenesis ,Cancer research ,Disease Progression ,Tumor necrosis factor alpha ,Female - Abstract
Background Esophageal carcinoma is the eighth prevalent malignancy and ranks the sixth in carcinoma-related death worldwide. Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2) has been identified as a tumor suppressor in multiple carcinomas. However, its roles and molecular mechanisms underlying esophageal carcinoma progression are still undefined till now. Methods RT-qPCR assay was employed to detect the expression of TIPE2 mRNA. TIPE2 protein expression was measured by using western blot assay. Ad-V and Ad-TIPE2 adenoviruses were constructed to overexpress TIPE2. The effects of TIPE2 overexpression on cell proliferation, invasion and apoptosis were assessed by MTT and Edu incorporation assays, transwell invasion assay and flow cytometry analysis, respectively. The effect of TIPE2 overexpression on xenograft tumor growth was determined by measuring tumor volume and weight, together with immunohistochemistry assay. The effect of TIPE2 overexpression on the Wnt/β-catenin signaling pathway was evaluated by detecting the protein levels of β-catenin, c-Myc and cyclinD1 in EC9076 cells and xenograft tumors of esophageal carcinoma. Results TIPE2 expression was downregulated in esophageal carcinoma tissues and cells. Adenovirus-mediated TIPE2 overexpression suppressed cell proliferation and invasion, and induced apoptosis in esophageal carcinoma cells. Enforced expression of TIPE2 inhibited tumor growth in vivo, as evidenced by the reduced tumor volume, tumor weight and proliferating cell nuclear antigen expression. Overexpression of TIPE2 inhibited the Wnt/β-catenin signaling pathway in esophageal carcinoma in vitro and in vivo. Conclusions These results suggest that TIPE2 suppressed progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.